Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
NeoGenomics
NEO
NeoGenomics
Underutilized Pharma Services And Execution Risks Will Threaten Demand Yet Efficiency Will Emerge
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
07 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$6.50
4.0% undervalued
intrinsic discount
10 Aug
US$6.24
Loading
1Y
-60.6%
7D
13.7%
Author's Valuation
US$6.5
4.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$6.5
4.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-147m
877m
2014
2017
2020
2023
2025
2026
2028
Revenue US$877.5m
Earnings US$47.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.34%
Healthcare Services revenue growth rate
0.28%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$47.94m
Earnings '28
x
21.79x
PE Ratio '28
=
US$1.04b
Market Cap '28
US$1.04b
Market Cap '28
/
132.29m
No. shares '28
=
US$7.90
Share Price '28
US$7.90
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$6.49
Fair Value '25
